HUTCHMED (China) (HCM) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
HUTCHMED (China) (HCM) has outperformed SIGA Technologies (SIGA) over the past year, losing 12.0% versus a loss of 61.2%. Over five years, SIGA leads with a -53.9% price change compared with -56.3% for HCM. HUTCHMED (China) is the larger company by market cap ($2.45 billion vs $235.7 million), about 10.4 times the size.
On valuation, SIGA Technologies trades at a lower forward P/E (3.0x vs 54.4x for HUTCHMED (China)).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | SIGA |
|---|---|---|
| Share price | $14.10 | $3.28 |
| Market cap | $2.45B | $235.67M |
| 1-day change | +3.15% | 0.00% |
| YTD return | +5.78% | -46.32% |
| 1-year return | -11.99% | -61.18% |
| 5-year return | -56.35% | -53.87% |
| P/E ratio (TTM) | 141.00 | — |
| Forward P/E | 54.40 | 3.04 |
| EPS (TTM) | $0.10 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | — |
| Revenue growth (YoY) | -12.96% | — |
| Net income (latest FY) | $456.91M | — |
| Gross margin | 38.68% | — |
| Operating margin | -7.14% | — |
| Net margin | 83.30% | — |
| 52-week high | $16.33 | $8.55 |
| 52-week low | $9.77 | $2.83 |
| Distance from 52-week high | -13.66% | -61.64% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +56.10% | — |
| Average volume | 68.22K | 724.21K |
| Shares outstanding | 173.81M | 71.85M |
| Employees | 1,790 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HUTCHMED (China) is about 10.4 times larger than SIGA Technologies by market value ($2.45B vs $235.67M).
- HCM has outperformed SIGA by 49.2 percentage points over the past year.
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
HCM vs SIGA FAQ
Which is bigger, HUTCHMED (China) or SIGA Technologies?
HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.45B compared with $235.67M for SIGA Technologies (SIGA).
Which stock has performed better over the past year, HCM or SIGA?
HCM returned -11.99% over the past 12 months, compared with -61.18% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.